Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.
Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, Russell TA, Eckardt MA, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM.
Igarashi K, et al. Among authors: eilber fc.
Oncotarget. 2017 Dec 4;9(8):7774-7781. doi: 10.18632/oncotarget.22892. eCollection 2018 Jan 30.
Oncotarget. 2017.
PMID: 29487690
Free PMC article.